Oxford Study: Vaxxes Cause Myocarditis Deaths By Mrs Vera West

Although giving the usual caveats, as mainstream medical publications do, that it is rare for SARS-CoV-2 infections to cause myocarditis, hear inflation, a recent study goes on to show that the Covid-19 vaccine is four times more likely to cause myocarditis in men under the age of 40 than a Covid-19 infection. The University of Oxford study is the first to acknowledged that people are actually dying from vaccine-induced myocarditis, something Covid critics have been discussing for some time now.

https://gellerreport.com/2022/09/oxford-study-vaccines-cause-myocarditis-deaths.html/?lctg=23533907

“In rare cases, a SARS-COV-2 infection can cause myocarditis. COVID-19 vaccines are also known to cause it. But when you compare the two—a COVID-19 infection versus a COVID vaccine—the medical consensus is that an infection is 14 times more likely to cause myocarditis. But a new study is challenging these numbers.

A new University of Oxford study published in the American Heart Association journal Circulation found that a COVID-19 vaccine is actually four times more likely to cause myocarditis in men under the age of 40 than a COVID-19 infection. This is also the first study that has acknowledged that people are actually dying from vaccine-induced myocarditis.

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.059970

Abstract

Background:

Myocarditis is more common after severe acute respiratory syndrome coronavirus 2 infection than after COVID-19 vaccination, but the risks in younger people and after sequential vaccine doses are less certain.

Methods:

A self-controlled case series study of people ages 13 years or older vaccinated for COVID-19 in England between December 1, 2020, and December 15, 2021, evaluated the association between vaccination and myocarditis, stratified by age and sex. The incidence rate ratio and excess number of hospital admissions or deaths from myocarditis per million people were estimated for the 1 to 28 days after sequential doses of adenovirus (ChAdOx1) or mRNA-based (BNT162b2, mRNA-1273) vaccines, or after a positive SARS-CoV-2 test.

Results:

In 42 842 345 people receiving at least 1 dose of vaccine, 21 242 629 received 3 doses, and 5 934 153 had SARS-CoV-2 infection before or after vaccination. Myocarditis occurred in 2861 (0.007%) people, with 617 events 1 to 28 days after vaccination. Risk of myocarditis was increased in the 1 to 28 days after a first dose of ChAdOx1 (incidence rate ratio, 1.33 [95% CI, 1.09–1.62]) and a first, second, and booster dose of BNT162b2 (1.52 [95% CI, 1.24–1.85]; 1.57 [95% CI, 1.28–1.92], and 1.72 [95% CI, 1.33–2.22], respectively) but was lower than the risks after a positive SARS-CoV-2 test before or after vaccination (11.14 [95% CI, 8.64–14.36] and 5.97 [95% CI, 4.54–7.87], respectively). The risk of myocarditis was higher 1 to 28 days after a second dose of mRNA-1273 (11.76 [95% CI, 7.25–19.08]) and persisted after a booster dose (2.64 [95% CI, 1.25–5.58]). Associations were stronger in men younger than 40 years for all vaccines. In men younger than 40 years old, the number of excess myocarditis events per million people was higher after a second dose of mRNA-1273 than after a positive SARS-CoV-2 test (97 [95% CI, 91–99] versus 16 [95% CI, 12–18]). In women younger than 40 years, the number of excess events per million was similar after a second dose of mRNA-1273 and a positive test (7 [95% CI, 1–9] versus 8 [95% CI, 6–8]).

Conclusions:

Overall, the risk of myocarditis is greater after SARS-CoV-2 infection than after COVID-19 vaccination and remains modest after sequential doses including a booster dose of BNT162b2 mRNA vaccine. However, the risk of myocarditis after vaccination is higher in younger men, particularly after a second dose of the mRNA-1273 vaccine.”